Feasibility Study on the Use of Redormin®500 on Day-time Cognition

NCT05684523 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Sleep Disorders, Circadian Rhythm
Cognitive Dysfunction

Interventions

DRUG: Valerian-Hop Extract
DRUG: Placebo

Sponsor

Max Zeller Soehne AG

Collaborators

[object Object]